GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (FRA:JSS) » Definitions » Retained Earnings

Nxera Pharma Co (FRA:JSS) Retained Earnings : €-119.0 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Nxera Pharma Co's retained earnings for the quarter that ended in Mar. 2024 was €-119.0 Mil.

Nxera Pharma Co's quarterly retained earnings declined from Sep. 2023 (€-100.7 Mil) to Dec. 2023 (€-102.6 Mil) and declined from Dec. 2023 (€-102.6 Mil) to Mar. 2024 (€-119.0 Mil).

Nxera Pharma Co's annual retained earnings increased from Dec. 2021 (€-75.9 Mil) to Dec. 2022 (€-62.4 Mil) but then declined from Dec. 2022 (€-62.4 Mil) to Dec. 2023 (€-102.6 Mil).


Nxera Pharma Co Retained Earnings Historical Data

The historical data trend for Nxera Pharma Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Retained Earnings Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -101.17 -85.41 -75.94 -62.35 -102.56

Nxera Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.06 -71.64 -100.74 -102.56 -119.04

Nxera Pharma Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Nxera Pharma Co  (FRA:JSS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Nxera Pharma Co (FRA:JSS) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (FRA:JSS) Headlines

No Headlines